DBV TECHNOLOGIES S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8317 USD | +3.96% |
|
+3.70% | -56.35% |
| Sales 2024 * | 6.01M 6.55M | Sales 2025 * | 5.4M 5.88M | Capitalization | 75.93M 82.77M |
|---|---|---|---|---|---|
| Net income 2024 * | -126M -137M | Net income 2025 * | -123M -134M | EV / Sales 2024 * | -11.5 x |
| Net cash position 2024 * | 145M 158M | Net cash position 2025 * | 116M 127M | EV / Sales 2025 * | -7.51 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 105 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.92% |
More Fundamentals
* Assessed data
More news
Latest transcript on DBV Technologies S.A.
More recommendations
More press releases
More news
| 1 day | +3.96% | ||
| 1 week | +3.70% | ||
| Current month | +3.83% | ||
| 1 month | -16.62% | ||
| 3 months | -40.17% | ||
| 6 months | -53.79% | ||
| Current year | -56.35% |
1 week
0.70
0.85
1 month
0.501.03
Current year
0.501.98
1 year
0.503.70
3 years
0.5011.98
5 years
0.5026.98
10 years
0.50101.14
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Tassé
CEO | Chief Executive Officer | 64 | 18-11-28 |
| Director of Finance/CFO | 54 | Nov. 05 | |
| Chief Operating Officer | - | Nov. 30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Timothy Morris
BRD | Director/Board Member | 62 | 21-02-28 |
Michel de Rosen
CHM | Chairman | 73 | 18-06-21 |
Don Soland
BRD | Director/Board Member | 65 | 15-03-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-15 | 0.8317 | +3.96% | 26,861 |
| 24-07-12 | 0.8 | +0.93% | 10,030 |
| 24-07-11 | 0.7926 | -0.91% | 39,271 |
| 24-07-10 | 0.7999 | +2.42% | 116,576 |
| 24-07-09 | 0.781 | -2.62% | 7,332 |
Delayed Quote Nasdaq, July 15, 2024 at 04:30 pm EDT
More quotes
DBV Technologies specializes in developing solutions for diagnosing and treating food allergies (primarily to peanuts and cow's milk) using a patch (Viaskin®) that administers active ingredients into the top layers of the skin.
Sector
Pharmaceuticals
Calendar
2024-07-28
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.789
EUR
Average target price
6
EUR
Spread / Average Target
+660.46%
| 1st Jan change | Capi. | |
|---|---|---|
| +5.55% | 72.01B | |
| +30.80% | 10.39B | |
| +41.28% | 5.26B | |
| -18.53% | 4.64B | |
| +18.24% | 3.7B | |
| +26.86% | 2.3B | |
| -39.52% | 1.8B | |
| -45.54% | 1.7B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- DBV Stock
- DBVT Stock
